Agilent Technologies (A) is back in focus after being highlighted as a key supplier to the expanding cannabis testing services market, along with a favorable analyst rank that points to improving earnings expectations and renewed investor interest.

The recent focus on Agilent Technologies as a key provider to cannabis testing services has coincided with a 19.31% 1 month share price return and a 35.39% 90 day share price return. The 1 year total shareholder return of 31.52% points to building momentum from both recent and longer term performance.

If you are tracking how regulation and lab demand shape new opportunities, it can be useful to widen your watchlist through the 42 healthcare AI stocks

Agilent Technologies now combines a strong life sciences and lab services business with a sharp re rating after recent gains. The real question is whether that quality and growth exposure are already fully priced in.

Most Popular Narrative: 3.5% Undervalued

Agilent Technologies last closed at $155.41, while the most followed narrative anchors fair value at $161. This gap is small, but the story behind it is detailed.

Strategic investments in higher-margin recurring revenue streams, including consumables, software, services, and digital platforms, are gaining traction, with CrossLab and services delivering consistent mid-single-digit growth and high customer satisfaction, indicating further margin expansion and greater earnings stability in future periods.

Want to see what justifies that projected uplift in earnings and value? The narrative focuses on recurring revenue, richer margins, and a tighter profit engine.

Result: Fair Value of $161 (UNDERVALUED)

However, Agilent Technologies still faces pressure from higher tariffs and supply chain complexity, along with tighter research funding that could weaken the current earnings story.

Another View on Agilent Technologies Valuation

The first narrative leans on future earnings and fair value of $161, but the current P/E of 31x is above the fair ratio of 24x even though it is below the Global Life Sciences average of 37.7x and the peer average of 35.7x. Is the market already paying up for this story?

For a closer look at how this current pricing compares with the fair ratio and sector, it helps to walk through the detailed valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the sentiment around Agilent Technologies so far feels confident, it still pays to look at the full picture yourself and move quickly. To see what the current optimism is based on, review the 3 key rewards

Looking For More Investment Ideas Beyond Agilent Technologies?

If you are serious about finding your next opportunity, it helps to cast the net wider and compare Agilent Technologies with other focused stock ideas built from clear fundamentals.

• Target reliable growth potential by checking companies that appear in the 52 high quality undervalued stocks.
• Strengthen your downside protection by reviewing stocks filtered through the 78 resilient stocks with low risk scores.
• Spot early opportunities before the crowd by scanning the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.